Age: 14.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Vaccination site erythema, Vaccination site swelling, Vaccination site warmth
Clinical narrative: Patient came home from school on 9/20/24 with fever of 100.2; swelling; redness; general malaise; heat, and tenderness at the injection site on the left arm/Localized heat; localized rash; tenderness at the injection site on the left arm; arm soreness/pain had persistent/ pain started to spread outside the drawn line.; This spontaneous case was reported by an other health care professional and describes the occurrence of MALAISE (general malaise), VACCINATION SITE WARMTH (heat, and tenderness at the injection site on the left arm/Localized heat), RASH (localized rash), INJECTION SITE PAIN (tenderness at the injection site on the left arm) and PAIN IN EXTREMITY (arm soreness/pain had persistent/ pain started to spread outside the drawn line.) in a 14-year-old female patient who received mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 19-Sep-2024, the patient received dose of mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (unknown route) 1 dosage form. In September 2024, the patient experienced MALAISE (general malaise), VACCINATION SITE WARMTH (heat, and tenderness at the injection site on the left arm/Localized heat), RASH (localized rash), INJECTION SITE PAIN (tenderness at the injection site on the left arm), PAIN IN EXTREMITY (arm soreness/pain had persistent/ pain started to spread outside the drawn line.), VACCINATION SITE SWELLING (swelling) and VACCINATION SITE ERYTHEMA (redness). On 20-Sep-2024,  after starting mRNA-1273.712 (SPIKEVAX 2024-2025 PFS), the patient experienced PYREXIA (Patient came home from school on 9/20/24 with fever of 100.2). The patient was treated with CEPHALEXIN [CEFALEXIN] at a dose of 10 milliliter every twelve hours. On 21-Sep-2024, PYREXIA (Patient came home from school on 9/20/24 with fever of 100.2) had resolved. At the time of the report, MALAISE (general malaise), VACCINATION SITE WARMTH (heat, and tenderness at the injection site on the left arm/Localized heat), INJECTION SITE PAIN (tenderness at the injection site on the left arm), VACCINATION SITE SWELLING (swelling) and VACCINATION SITE ERYTHEMA (redness) had not resolved and RASH (localized rash) and PAIN IN EXTREMITY (arm soreness/pain had persistent/ pain started to spread outside the drawn line.) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 20-Sep-2024, Body temperature: 100.2.     For mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. Patient had symptoms approximately 12 hours later. No additional symptoms were reported.  Ice was applied to the injection site.  No further interventions were attempted at the time of reporting. On 21-Sep-2024, patient was taken to urgent care as the redness, heat and pain started to spread outside the drawn line.   Most recent FOLLOW-UP information incorporated above includes: On 23-Sep-2024: Live significant follow-up received. Added new events pyrexia, vaccination site swelling, vaccination site erythema. Added lab data. Added treatment drug Cephalexin. Updated narrative.